Director: Vallerie Victoria Mclaughlin, M.D.
The Pulmonary Hypertension Program at the University of Michigan Health System is a multi-disciplinary program developed in 1994 to diagnosis and manage patients with primary and secondary forms of pulmonary hypertension (PH). We are a referral center for hospitals and physicians throughout Michigan and Northern Ohio.
The working group from Cardiology, Pulmonary and Critical Care Medicine, Radiology, Thoracic Surgery, Hematology, and Rheumatology has fostered significant enhancements in patient care and research in the diagnosis, risk stratification, and management of primary pulmonary hypertension (PPH), thromboembolic hypertension, and PH associated with congenital heart disease, liver disease, and collagen vascular diseases.
Patients with PPH and secondary PH have the options of several FDA-approved and investigational protocols. We use high-dose calcium channel blocker therapy in patients with pulmonary vasodilator reserve to inhaled nitric oxide, and continuous intravenous infusion of epoprostenol or Flolan in NHYA class 3 and 4 non-responders with PPH and scleroderma-related disorders.
We offer the subcutaneous version of prostacyclin, Uniprost (investigational), in patients with PPH, Eisenmenger's, and secondary PH associated with liver disease, thromboemboli, scleroderma-related disorders and lupus.
Patients with known or suspected chronic thromboembolic pulmonary hypertension by clinical history, VQ scan and/or helical computer tomography often undergo pulmonary angiography with the additional use of intravascular ultrasound. Many patients have undergone successful pulmonary thromboendarterectomy. Using ultrasound-guided targets, we have successfully performed pulmonary artery angioplasty.
Office Number: 734-647-7321 Or Toll Free 1-888-287-1082
1500 East Medical Center Drive
Ann Arbor, MI 48109
Maps & Directions: